Postresection CA19-9 and margin status as predictors of recurrence after adjuvant treatment for pancreatic carcinoma: Analysis of NRG oncology RTOG trial 9704

PURPOSE: NRG Oncology RTOG 9704 was the first adjuvant trial to validate the prognostic value of postresection CA19-9 levels for survival in patients with pancreatic carcinoma. The data resulting from this study also provide information about predictors of recurrence that may be used to tailor indiv...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Adv Radiat Oncol
Egile Nagusiak: Regine, William F., Winter, Kathryn, Abrams, Ross A., Safran, Howard, Kessel, Ivan L., Chen, Yuhchyau, Fugazzi, James A., Donnelly, Eric D., DiPetrillo, Thomas A., Narayan, Samir, Plastaras, John P., Gaur, Rakesh, Delouya, Guila, Suh, John H., Meyer, Joshua E., Haddock, Michael G., Didolkar, Mukund S., Padula, Gilbert D.A., Johnson, David, Hoffman, John P., Crane, Christopher H.
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Elsevier 2018
Gaiak:
Pancreas Tumor
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC6000159/
https://ncbi.nlm.nih.gov/pubmed/29904740
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.adro.2018.01.003
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak